SPRB Stock Forecast & Price Target

Spruce Biosciences is viewed favorably because TA-ERT is positioned as a leading emerging therapy for MPS IIIB, with FDA commentary signaling regulatory flexibility and precedent from full approval of Ultragenyx’s Fayuvi supporting the possibility that biomarker, natural-history, and clinical evidence can be sufficient for rare-disease approval. The company is advancing its 4Q26 BLA submission and TrAnsform confirmatory study, while steady CMC progress, including a successfully completed first PPQ batch, strengthens execution confidence ahead of a likely approval during 2H27. Financially, Spruce ended the quarter with $96M in cash, runway into 2H27, a $5.5M strategic investment for the EAP, and physician checks suggesting broad utilization with peak sales exceeding $300M.

Spruce Biosciences is viewed negatively because its ~$60M EV appears disconnected from the execution, regulatory, and commercial risks surrounding TA-ERT, even though approval next year is estimated at 75% POS and a PRV could be worth ~$150M+. The case still depends on FDA acceptance of accelerated approval via Phase 2 surrogate data, with unclear precedent in MPS IIIB and meaningful CMC and weekly ICV administration burdens that could limit uptake. Financially, 2Q26 OpEx of $17M and a $16M net loss underscore continued cash burn, while the company’s limited pipeline and likely need for additional capital heighten dilution risk.